NASDAQ · Financial Statements
ADMA Biologics Inc (ADMA) Financial Statements
$10.68
NASDAQ: ADMA
Market Cap $2.39B
Overview Financials Dividend
ADMA Biologics Inc most recently reported annual revenue of $510.0M, net profit of $147.0M. Revenue grew at an average annual rate of 64.8% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $81.0M $154.0M $258.0M $426.0M $510.0M Operating Profit $-58.0M $-39.0M $22.0M $139.0M $191.0M Net Profit $-72.0M $-66.0M $-28.0M $198.0M $147.0M EPS $-0.61 $-0.43 $-0.13 $0.81 $0.60 Op Margin -72.1% -25.6% 8.4% 32.6% 37.5%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $276.0M $348.0M $329.0M $489.0M $624.0M Total Liabilities $135.0M $196.0M $194.0M $140.0M $147.0M Cash $51.0M $87.0M $51.0M $103.0M $88.0M Borrowings $103.0M $154.0M $141.0M $82.0M $80.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-112.0M $-60.0M $9.0M $119.0M $50.0M Investing Cash Flow $-27.0M $-28.0M $-10.0M $-17.0M $-44.0M Financing Cash Flow $0 $-8.0M $-15.0M $-6.0M $-44.0M Net Cash Flow $-5.0M $35.0M $-35.0M $52.0M $-16.0M Free Cash Flow $-126.0M $-73.0M $4.0M $110.0M $28.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.82 EV / EBITDA 10.29 FCF Yield 4.96% Quick Ratio 3.81 Interest Coverage 24.53 Return 1Y -52.03% Return 3Y 121.18% Return 5Y 412.42%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .